Stevanato Group S.p.A.
STVN Healthcare Medical Instruments & Supplies
Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
- Revenue
- +5.91%
- EPS
- +17.5%
- Free cash flow
- +4,089.9%
- Total debt
- +2.85%
Quarter to September 2026, against a year earlier
Follow STVN
Alert me
Stevanato Group S.p.A. (STVN) P/E ratio
As of 5 November 2026, Stevanato Group S.p.A. (STVN) trades at a P/E ratio of 22.4×. Over the past ten years it has ranged from 22.4× (November 2026) to 61.2× (August 2023) — the current reading is the lowest in ten years. That is below the Medical Instruments & Supplies industry median of 30.3× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 34.7× | (23.58%) |
| FY2024 | 45.4× | 0.80% |
| FY2023 | 45.0× | 44.19% |
| FY2022 | 31.2× | (11.91%) |
| FY2021 | 35.5× | (7.50%) |
| FY2020 | 38.3× | 0.00% |
| FY2019 | 38.3× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 35.8× | 10.90% |
| Jun 2026 | 32.3× | 38.46% |
| Mar 2026 | 23.3× | (32.82%) |
| Dec 2025 | 34.7× | (23.21%) |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PLSE Pulse Biosciences, Inc compare | n/m |
| MMED MiniMed Group, Inc. compare | n/m |
| TFX Teleflex Incorporated compare | n/m |
| NVST Envista Holdings Corporation compare | 6.4× |
| STVN Stevanato Group S.p.A. | 22.4× |
| MMSI Merit Medical Systems, Inc. compare | 33.2× |
| ICUI ICU Medical, Inc. compare | 69.3× |
| ATRC AtriCure, Inc. compare | 199× |
| WRBY Warby Parker Inc. compare | 434× |
| Medical Instruments & Supplies industry median | 30.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on STVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement